Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Study to Evaluate the Food Effect on Pharmacokinetics Profile and Safety of CKD-393

Phase 1

Completed

Conditions: Type II Diabetes Mellitus

Interventions: Drug: CKD-393

First Posted Date: 2022-03-11

Last Posted Date: 2022-11-30

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 28

Registration Number: NCT05274880

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg

Phase 1

Completed

Conditions: Hypertension and Dyslipidemia

Interventions: Drug: CKD-386(3)
Drug: D013, D326, D337

First Posted Date: 2022-02-17

Last Posted Date: 2022-09-28

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 64

Registration Number: NCT05245084

Locations: 🇰🇷
H plus Yangji hospital, Seoul, Korea, Republic of

CKD-506 Drug-Drug Interaction Study in Healthy Male Subjects

Phase 1

Completed

Conditions: Drug Drug Interaction

Interventions: Drug: Midazolam
Drug: CKD-506

First Posted Date: 2022-02-14

Last Posted Date: 2022-08-25

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 17

Registration Number: NCT05238948

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930

Phase 1

Completed

Conditions: Glaucoma

Interventions: Drug: D565
Drug: D930

First Posted Date: 2022-01-26

Last Posted Date: 2023-01-05

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 32

Registration Number: NCT05207761

Locations: 🇰🇷
Seoul National University College of Medicine and Hospital, Seoul, Korea, Republic of

Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients

Phase 4

Conditions: Kidney Transplantation

Interventions: Drug: Mycophenolate mofetil
Drug: Sirolimus

First Posted Date: 2022-01-18

Last Posted Date: 2022-02-01

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 206

Registration Number: NCT05193565

Locations: 🇰🇷
The Catholic University of Korea, Seoul, St.Mary's Hospital, Seoul, Korea, Republic of

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)

Phase 1

Completed

Conditions: Hypertension and Dyslipidemia

Interventions: Drug: CKD-348(3)
Drug: CKD-828, D097, D337

First Posted Date: 2022-01-14

Last Posted Date: 2023-06-09

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 63

Registration Number: NCT05192356

Locations: 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects

Phase 1

Completed

Conditions: Chronic Hepatitis b

Interventions: Drug: D418 Tab.
Drug: CKD-388 Tab.

First Posted Date: 2022-01-12

Last Posted Date: 2022-09-28

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 65

Registration Number: NCT05189288

Locations: 🇰🇷
H plus Yangji hospital, Seoul, Korea, Republic of

Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: CKD-393
Drug: CKD-501, D759, H053

First Posted Date: 2021-11-09

Last Posted Date: 2023-06-09

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 33

Registration Number: NCT05113693

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects

Phase 1

Conditions: GERD

Interventions: Drug: CKD-382, D860, D027

First Posted Date: 2021-11-04

Last Posted Date: 2021-11-04

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 42

Registration Number: NCT05108038

Locations: 🇰🇷
Chungbuk Ntional University Hospital, Cheongju-si, Korea, Republic of

Study to Evaluate the Safety and Pharmacokinetics of CKD-349 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Chronic Heart Failure

Interventions: Drug: D113
Drug: CKD-349

First Posted Date: 2021-10-22

Last Posted Date: 2022-10-07

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 71

Registration Number: NCT05089279

Locations: 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy